MTHFD2 Antibody (D-4): sc-515167

MTHFD2 Antibody (D-4) is a mouse monoclonal IgG1 antibody that detects MTHFD2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MTHFD2, also known as NMDMC, is a crucial bifunctional protein composed of 350 amino acids, playing a vital role in the interconversion of tetrahydrofolate derivatives, which are essential for the synthesis of purine, methionine, and thymidylate. MTHFD2 exhibits both methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate cyclohydrolase activities, requiring NADP or NAD as cofactors for enzymatic functions. The activity of these cofactors is influenced by intracellular concentrations of magnesium and phosphate, highlighting the importance of cellular ion balance in metabolic processes. MTHFD2 operates as a homodimer and is predominantly localized in the mitochondria, where MTHFD2 is expressed during the development of normal tissue, underscoring its significance in cellular metabolism and energy production. Anti-MTHFD2 antibody (D-4) is an invaluable tool for researchers studying metabolic pathways and mitochondrial function in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MTHFD2 Antibody (D-4) References:

1. Upregulation of miR-504-3p is associated with favorable prognosis of acute myeloid leukemia and may serve as a tumor suppressor by targeting MTHFD2.  |  Li, SM., et al. 2019. Eur Rev Med Pharmacol Sci. 23: 1203-1213. PMID: 30779090
2. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.  |  Yu, C., et al. 2020. J Cell Mol Med. 24: 1568-1577. PMID: 31778025
3. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell.  |  Wan, X., et al. 2020. Cell Death Dis. 11: 649. PMID: 32811824
4. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.  |  Shi, Y., et al. 2021. J Cell Mol Med. 25: 7013-7027. PMID: 34121323
5. PPFIA4 promotes castration-resistant prostate cancer by enhancing mitochondrial metabolism through MTHFD2.  |  Zhao, R., et al. 2022. J Exp Clin Cancer Res. 41: 125. PMID: 35382861
6. Knockdown of MTHFD2 inhibits proliferation and migration of nasopharyngeal carcinoma cells through the ERK signaling pathway.  |  Wu, S., et al. 2022. Biochem Biophys Res Commun. 614: 47-55. PMID: 35567943
7. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer.  |  Achreja, A., et al. 2022. Nat Metab. 4: 1119-1137. PMID: 36131208
8. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.  |  Shi, X., et al. 2023. Front Immunol. 14: 1326509. PMID: 38130721
9. Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway.  |  Wang, J., et al. 2024. Front Biosci (Landmark Ed). 29: 35. PMID: 38287824
10. Implications of MTHFD2 expression in renal cell carcinoma aggressiveness.  |  Silva, RVN., et al. 2024. PLoS One. 19: e0299353. PMID: 38422037

The preferred MTHFD2 antibody is MTHFD2 Antibody (A-2): sc-390708.